Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation

J. J. Heger, E. N. Prystowsky, W. M. Jackman, G. V. Naccarelli, K. A. Warfel, R. L. Rinkenberger, D. P. Zipes

Research output: Contribution to journalArticle

441 Citations (Scopus)

Abstract

We evaluated the effects of amiodarone in 45 patients with recurrent ventricular tachycardia or ventricular fibrillation. At a mean follow-up time of 12.7±8.8 months (range, three to 36), amiodarone was successful in nine of 16 patients with recurrent ventricular tachycardia. During amiodarone therapy, ventricular tachycardia could be induced in 18 of 19 patients in whom it had been induced before therapy, but only six of these 19 had spontaneous recurrence during follow-up. side effects included corneal microdeposits, hyperthyroidism, blue skin, nausea, and symptomatic bradycardia. Pulmonary fibrosis occurred in three patients. Doses of up to 2000 mg a day did not produce cardiac toxicity, but neurologic side effects precluded long-term therapy at this dose. We conclude that amiodarone is effective for long-term therapy of recurrent ventricular tachyarrhythmias, that induction of arrhythmia during therapy does not always predict efficacy, and that side effects are frequent but do not usually limit therapy.

Original languageEnglish (US)
Pages (from-to)539-545
Number of pages7
JournalNew England Journal of Medicine
Volume305
Issue number10
StatePublished - 1981
Externally publishedYes

Fingerprint

Electrophysiology
Ventricular Fibrillation
Ventricular Tachycardia
Amiodarone
Therapeutics
Pulmonary Fibrosis
Hyperthyroidism
Bradycardia
Tachycardia
Nausea
Nervous System
Cardiac Arrhythmias
Recurrence
Skin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Heger, J. J., Prystowsky, E. N., Jackman, W. M., Naccarelli, G. V., Warfel, K. A., Rinkenberger, R. L., & Zipes, D. P. (1981). Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. New England Journal of Medicine, 305(10), 539-545.

Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. / Heger, J. J.; Prystowsky, E. N.; Jackman, W. M.; Naccarelli, G. V.; Warfel, K. A.; Rinkenberger, R. L.; Zipes, D. P.

In: New England Journal of Medicine, Vol. 305, No. 10, 1981, p. 539-545.

Research output: Contribution to journalArticle

Heger, JJ, Prystowsky, EN, Jackman, WM, Naccarelli, GV, Warfel, KA, Rinkenberger, RL & Zipes, DP 1981, 'Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation', New England Journal of Medicine, vol. 305, no. 10, pp. 539-545.
Heger JJ, Prystowsky EN, Jackman WM, Naccarelli GV, Warfel KA, Rinkenberger RL et al. Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. New England Journal of Medicine. 1981;305(10):539-545.
Heger, J. J. ; Prystowsky, E. N. ; Jackman, W. M. ; Naccarelli, G. V. ; Warfel, K. A. ; Rinkenberger, R. L. ; Zipes, D. P. / Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. In: New England Journal of Medicine. 1981 ; Vol. 305, No. 10. pp. 539-545.
@article{71cc4c0316a54c98918eed1628d3c905,
title = "Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation",
abstract = "We evaluated the effects of amiodarone in 45 patients with recurrent ventricular tachycardia or ventricular fibrillation. At a mean follow-up time of 12.7±8.8 months (range, three to 36), amiodarone was successful in nine of 16 patients with recurrent ventricular tachycardia. During amiodarone therapy, ventricular tachycardia could be induced in 18 of 19 patients in whom it had been induced before therapy, but only six of these 19 had spontaneous recurrence during follow-up. side effects included corneal microdeposits, hyperthyroidism, blue skin, nausea, and symptomatic bradycardia. Pulmonary fibrosis occurred in three patients. Doses of up to 2000 mg a day did not produce cardiac toxicity, but neurologic side effects precluded long-term therapy at this dose. We conclude that amiodarone is effective for long-term therapy of recurrent ventricular tachyarrhythmias, that induction of arrhythmia during therapy does not always predict efficacy, and that side effects are frequent but do not usually limit therapy.",
author = "Heger, {J. J.} and Prystowsky, {E. N.} and Jackman, {W. M.} and Naccarelli, {G. V.} and Warfel, {K. A.} and Rinkenberger, {R. L.} and Zipes, {D. P.}",
year = "1981",
language = "English (US)",
volume = "305",
pages = "539--545",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "10",

}

TY - JOUR

T1 - Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation

AU - Heger, J. J.

AU - Prystowsky, E. N.

AU - Jackman, W. M.

AU - Naccarelli, G. V.

AU - Warfel, K. A.

AU - Rinkenberger, R. L.

AU - Zipes, D. P.

PY - 1981

Y1 - 1981

N2 - We evaluated the effects of amiodarone in 45 patients with recurrent ventricular tachycardia or ventricular fibrillation. At a mean follow-up time of 12.7±8.8 months (range, three to 36), amiodarone was successful in nine of 16 patients with recurrent ventricular tachycardia. During amiodarone therapy, ventricular tachycardia could be induced in 18 of 19 patients in whom it had been induced before therapy, but only six of these 19 had spontaneous recurrence during follow-up. side effects included corneal microdeposits, hyperthyroidism, blue skin, nausea, and symptomatic bradycardia. Pulmonary fibrosis occurred in three patients. Doses of up to 2000 mg a day did not produce cardiac toxicity, but neurologic side effects precluded long-term therapy at this dose. We conclude that amiodarone is effective for long-term therapy of recurrent ventricular tachyarrhythmias, that induction of arrhythmia during therapy does not always predict efficacy, and that side effects are frequent but do not usually limit therapy.

AB - We evaluated the effects of amiodarone in 45 patients with recurrent ventricular tachycardia or ventricular fibrillation. At a mean follow-up time of 12.7±8.8 months (range, three to 36), amiodarone was successful in nine of 16 patients with recurrent ventricular tachycardia. During amiodarone therapy, ventricular tachycardia could be induced in 18 of 19 patients in whom it had been induced before therapy, but only six of these 19 had spontaneous recurrence during follow-up. side effects included corneal microdeposits, hyperthyroidism, blue skin, nausea, and symptomatic bradycardia. Pulmonary fibrosis occurred in three patients. Doses of up to 2000 mg a day did not produce cardiac toxicity, but neurologic side effects precluded long-term therapy at this dose. We conclude that amiodarone is effective for long-term therapy of recurrent ventricular tachyarrhythmias, that induction of arrhythmia during therapy does not always predict efficacy, and that side effects are frequent but do not usually limit therapy.

UR - http://www.scopus.com/inward/record.url?scp=0019846135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019846135&partnerID=8YFLogxK

M3 - Article

C2 - 6789201

AN - SCOPUS:0019846135

VL - 305

SP - 539

EP - 545

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 10

ER -